Suppr超能文献

非小细胞肺癌发病机制及进展中特定Toll样受体的分析

Analysis of Selected Toll-like Receptors in the Pathogenesis and Advancement of Non-Small-Cell Lung Cancer.

作者信息

Smok-Kalwat Jolanta, Mertowska Paulina, Mertowski Sebastian, Góźdź Stanisław, Korona-Głowniak Izabela, Kwaśniewski Wojciech, Grywalska Ewelina

机构信息

Department of Clinical Oncology, Holy Cross Cancer Centre, 3 Artwinskiego Street, 25-734 Kielce, Poland.

Department of Experimental Immunology, Medical University of Lublin, 4a Chodzki Street, 20-093 Lublin, Poland.

出版信息

J Clin Med. 2024 May 9;13(10):2793. doi: 10.3390/jcm13102793.

Abstract

(1) Non-small-cell lung cancer (NSCLC) represents a significant global health challenge, contributing to numerous cancer deaths. Despite advances in diagnostics and therapy, identifying reliable biomarkers for prognosis and therapeutic stratification remains difficult. Toll-like receptors (TLRs), crucial for innate immunity, now show potential as contributors to cancer development and progression. This study aims to investigate the role of TLR expression as potential biomarkers in the development and progression of NSCLC. (2) The study was conducted on 89 patients diagnosed with NSCLC and 40 healthy volunteers, for whom the prevalence of TLR2, TLR3, TLR4, TLR7, TLR8, and TLR9 was assessed on selected subpopulations of T and B lymphocytes in the peripheral blood of recruited patients along with the assessment of their serum concentration. (3) Our study showed several significant changes in NSCLC patients at the beginning of the study. This resulted in a 5-year follow-up of changes in selected TLRs in recruited patients. Due to the high mortality rate of NSCLC patients, only 16 patients survived the 5 years. (4) The results suggest that TLRs may constitute real biomarker molecules that may be used for future prognostic purposes in NSCLC. However, further validation through prospective clinical and functional studies is necessary to confirm their clinical utility. These conclusions may lead to better risk stratification and tailored interventions, benefiting NSCLC patients and bringing medicine closer to precision.

摘要

(1) 非小细胞肺癌(NSCLC)是一项重大的全球健康挑战,导致众多癌症死亡。尽管在诊断和治疗方面取得了进展,但确定可靠的预后和治疗分层生物标志物仍然困难。Toll样受体(TLR)对先天免疫至关重要,现在显示出对癌症发展和进展有促进作用的潜力。本研究旨在探讨TLR表达作为NSCLC发展和进展中潜在生物标志物的作用。(2) 该研究对89例诊断为NSCLC的患者和40名健康志愿者进行,评估了招募患者外周血中T和B淋巴细胞选定亚群上TLR2、TLR3、TLR4、TLR7、TLR8和TLR9的患病率,并评估了它们的血清浓度。(3) 我们的研究在研究开始时显示NSCLC患者有几个显著变化。这导致对招募患者中选定TLR的变化进行了5年随访。由于NSCLC患者的高死亡率,只有16名患者存活了5年。(4) 结果表明,TLR可能构成真正的生物标志物分子,可用于NSCLC未来预后目的。然而,需要通过前瞻性临床和功能研究进行进一步验证,以确认其临床效用。这些结论可能导致更好的风险分层和量身定制的干预措施,使NSCLC患者受益,并使医学更接近精准医学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9c9/11122486/b98b72ecd93a/jcm-13-02793-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验